Loading…
Loading…
GERM (ETFMG Treatments, Testing and Advancements ETF) is no longer actively trading.
This usually means the company was acquired and taken private, delisted from its exchange, or its ticker has been retired. Every price, valuation, dividend, and analyst figure on this page is frozen at the last available trading session and reads as historical reference — not a current-day signal.
See exactly how GERM's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for GERM and 80,000+ other tickers.
This fund aims to replicate the investment performance of U.S.-listed companies, including equity shares and depositary receipts, that are primarily engaged in two sectors: either researching, developing, and bringing to market treatments or vaccines for infectious diseases, or producing, researching, and supplying biological diagnostic tests for patients. At least 80% of the fund's total assets will be invested in the specific securities that constitute its underlying index. It is important to note that this fund is structured as non-diversified.
CHICAGO, Aug. 14, 2024 (GLOBE NEWSWIRE) -- Amplify ETFs, a leading provider of exchange traded funds, today announced the scheduled liquidation of three ETFs (the “Funds”). The Funds scheduled for liquidation include: ETF Name Ticker Amplify Emerging Markets FinTech ETF EMFQ Amplify Treatments, Testing and Advancements ETF GERM Amplify Inflation Fighter ETF IWIN Based on the recommendation of Amplify Investments LLC, the Funds' investment adviser, the Board of Trustees of the Amplify ETF Trust unanimously determined that it is in the best interests of the Funds and their shareholders to liquidate the Funds.
Sometimes it feels like it's Nvidia's world and we all just live in it. Why bother with anything else?
In June, the ETF industry learned that issuer ETF Managers Group would be selling its funds to Amplify ETFs. The transaction, once completed, will bring Amplify's total AUM to $8 billion invested across 29 ETFs.
The week ending Friday, July 21, has been busy for the ETF industry, though launches were muted. A total of seven funds rolled out, which suggests the market could be entering some kind of summer slump.
The FDA advised to Pfizer, Moderna and Novavax to manufacture single-strain jabs targeting the omicron subvariant XBB.1.5 should prove to be a victory for some biotech ETFs.